Biomaterial Database

Can intravenous cyclophosphamide be used for steroid-dependent nephrotic syndrome? 1997

Z Bircan, and M Soran, and M Kervancioglu, and G Gonlusen, and I Tuncer

UI	MeSH Term	Description	Entries
D007223	Infant	A child between 1 and 23 months of age.	Infants
D008297	Male		Males
D009402	Nephrosis, Lipoid	A kidney disease with no or minimal histological glomerular changes on light microscopy and with no immune deposits. It is characterized by lipid accumulation in the epithelial cells of KIDNEY TUBULES and in the URINE. Patients usually show NEPHROTIC SYNDROME indicating the presence of PROTEINURIA with accompanying EDEMA.	Glomerulonephritis, Minimal Change,Glomerulopathy, Minimal Change,Nephropathy, Minimal Change,Nephrotic Syndrome, Minimal Change,Idiopathic Minimal Change Nephrotic Syndrome,Minimal Change Disease,Minimal Change Glomerulopathy,Minimal Change Nephrotic Syndrome,Change Diseases, Minimal,Disease, Minimal Change,Diseases, Minimal Change,Glomerulonephritides, Minimal Change,Glomerulopathies, Minimal Change,Lipoid Nephroses,Lipoid Nephrosis,Minimal Change Diseases,Minimal Change Glomerulonephritides,Minimal Change Glomerulonephritis,Minimal Change Nephropathies,Minimal Change Nephropathy,Nephropathies, Minimal Change,Nephroses, Lipoid
D002675	Child, Preschool	A child between the ages of 2 and 5.	Children, Preschool,Preschool Child,Preschool Children
D003520	Cyclophosphamide	Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.	(+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000477	Alkylating Agents	Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.	Alkylating Agent,Alkylator,Alkylators,Agent, Alkylating,Agents, Alkylating
D013256	Steroids	A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons. Steroids have a common nucleus, a fused, reduced 17-carbon atom ring system, cyclopentanoperhydrophenanthrene. Most steroids also have two methyl groups and an aliphatic side-chain attached to the nucleus. (From Hawley's Condensed Chemical Dictionary, 11th ed)	Steroid,Catatoxic Steroids,Steroids, Catatoxic

Related Publications

Z Bircan, and M Soran, and M Kervancioglu, and G Gonlusen, and I Tuncer

Intravenous cyclophosphamide is the drug of choice for steroid dependent nephrotic syndrome.

February 2003, Pediatrics international : official journal of the Japan Pediatric Society,

Z Bircan, and M Soran, and M Kervancioglu, and G Gonlusen, and I Tuncer

Cyclophosphamide in steroid-dependent nephrotic syndrome.

June 2011, Pediatric nephrology (Berlin, Germany),

Z Bircan, and M Soran, and M Kervancioglu, and G Gonlusen, and I Tuncer

Steroid-dependent nephrotic syndrome and cyclophosphamide.

May 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,

Z Bircan, and M Soran, and M Kervancioglu, and G Gonlusen, and I Tuncer

Intravenous cyclophosphamide in steroid-resistant nephrotic syndrome.

April 2003, Pediatric nephrology (Berlin, Germany),

Z Bircan, and M Soran, and M Kervancioglu, and G Gonlusen, and I Tuncer

Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome.

May 2004, Pediatric nephrology (Berlin, Germany),

Z Bircan, and M Soran, and M Kervancioglu, and G Gonlusen, and I Tuncer

Levamisole vs. cyclophosphamide for frequently-relapsing steroid-dependent nephrotic syndrome.

October 2001, Clinical nephrology,

Z Bircan, and M Soran, and M Kervancioglu, and G Gonlusen, and I Tuncer

Unfavorable response to cyclophosphamide in steroid-dependent nephrotic syndrome.

August 2000, Pediatric nephrology (Berlin, Germany),